Jun 14, 2021 6:30am EDT BiomX Presents Preclinical Results With BX005 for Atopic Dermatitis at the Revolutionizing Atopic Dermatitis 2021 Virtual Conference and the International Conference on Phage Therapy and Bacteriophages
Jun 09, 2021 6:30am EDT BiomX to Present Preclinical Results with BX004 in Cystic Fibrosis at the 44th European Cystic Fibrosis Conference
May 24, 2021 6:30am EDT BiomX Reports First Quarter 2021 Financial Results and Provides Business Updates
May 18, 2021 8:00am EDT BiomX To Host Key Opinion Leader Event on BX003 for the Treatment of Inflammatory Bowel Disease
May 18, 2021 6:30am EDT BiomX to Host First Quarter 2021 Financial Results Conference Call and Webcast on May 24, 2021
Mar 31, 2021 6:30am EDT BiomX Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Mar 24, 2021 6:30am EDT BiomX to Report Fourth Quarter and Full Year 2020 Financial Results on March 31, 2021
Mar 02, 2021 7:00am EST BiomX Announces Dosing of First Subject in Phase 2 Study of BX001 for Acne-Prone Skin
